Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...

Eli Lilly and Company (NYSE: LLY) today announced that the highest approved doses of Zepbound (tirzepatide)—12.5 mg and 15 mg ...

Starting July 7, 2025, the two highest doses of Zepbound will be available for a flat price of $499 per month, with shipments ...

Through the Zepbound Self Pay Journey Program ... licensed to prescribe Lilly medicines and is listed as a pharmacy option in all major electronic health records (EHR) systems.

Eli Lilly will add 12.5 mg and 15 mg single-dose vials of its weight loss drug Zepbound to its LillyDirect platform starting July 7, completing the full range of approved doses. All vial doses, ...

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

The self-pay option in LillyDirect "enables a transparent ... Lilly's move comes as Zepbound seems to be building momentum in the market – with second-quarter sales of $1.2 billion, way ahead ...

Eli Lilly's drive to provide as many treatment options as possible for its weight-loss drug Zepbound has continued ... company's LillyDirect direct-to-consumer self-pay channel, $150 lower than ...

Eli Lilly expands Zepbound access with flat-rate pricing and new vial options, supporting wider obesity treatment access ...

Eli Lilly is reducing the price of the highest doses of its popular drug Zepbound for folks who aren't using insurance.